Ascendis Pharma A/S (ASND)

NASDAQ: ASND · Real-Time Price · USD

263.52

+2.28 (0.87%)

At close: Sep 11, 2026, 4:00 PM EDT

265.23

+1.72 (0.65%)

Pre-market: Sep 14, 2026, 7:37 AM EDT

Ascendis Pharma Financials Overview

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Revenue	1,047	720.13	363.64	266.72	51.17	7.78
Revenue Growth	113.35%	98.03%	36.34%	421.20%	557.93%	11.87%
Gross Profit	955.9	625.22	319.38	222.32	39.04	4.26
Operating Income	258.66	-136.27	-278.76	-455.54	-561.81	-451.79
Net Income	741.76	-228.03	-378.08	-481.45	-583.19	-383.58
Earnings Per Share	11.72	-3.76	-6.53	-8.55	-10.40	-7.00
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
YORVIPATH	778.78	477.41	28.73	-	-	-
SKYTROFA	203.29	206.16	197	178.66	35.66	0.94
Services and Clinical Supply	20.88	18.01	15.57	21.98	12.97	4.47
Licenses	6.53	5.63	122.34	66.08	2.55	2.37
Milestones	-	12.92	-	-	-	-
Revenue (Total)	1,047	720.13	363.64	266.72	51.17	7.78

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Cash & Investments	812.26	616.04	559.54	399.44	742.95	789.63
Total Debt	450.07	871.79	856.62	644.27	508.38	104.96
Net Cash (Debt)	362.19	-255.75	-297.07	-244.83	234.57	684.66
Net Cash Growth	-	-	-	-	-65.74%	-7.74%
Net Cash Per Share	5.72	-4.22	-5.13	-4.35	4.18	12.50

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Operating Cash Flow	349.51	53.9	-306.2	-467.36	-495.7	-417.65
Capital Expenditures	-14.39	-8.49	-1.43	-2.44	-14.49	-23.7
Free Cash Flow	335.12	45.41	-307.62	-469.8	-510.19	-441.35
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Gross Margin	91.30%	86.82%	87.83%	83.36%	76.28%	54.71%
Operating Margin	24.70%	-18.92%	-76.66%	-170.80%	-1097.85%	-5808.59%
Pretax Margin	9.34%	-29.53%	-102.64%	-177.77%	-1129.12%	-4936.28%
Profit Margin	70.84%	-31.67%	-103.97%	-180.51%	-1139.63%	-4931.56%
FCF Margin	32.01%	6.31%	-84.60%	-176.14%	-996.97%	-5674.38%